Sage Journals: Discover world-class research

Retricted access

Research article

First published 2014-6

Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis

G Izquierdo, P O’Connor, X Montalban [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-10

Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination

Elsa Mhanna, Agathe Nouchi, Céline Louapre [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2014-10

Fingolimod-associated amenorrhea: a report of three cases

R Alroughani

Multiple Sclerosis Journal

Retricted access

Other

First published 2010-02

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

G. Comi, P. O'Connor, X. Montalban [...]

Multiple Sclerosis Journal

Retricted access

Case report

First published 2016-12

Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod

Despoina Papathemeli, Ronald Gräfe, Uwe Hildebrandt [...]

Multiple Sclerosis Journal

Free access

Research article

First published 2017-4

Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects

Max J. Hilz, Ruihao Wang, Carmen de Rojas Leal [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2025

Switch from fingolimod to ozanimod for safety or intolerance reasons

Elisabetta Signoriello, Giuseppe Romano, Matteo Foschi [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2020-7

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

Oscar Fernández, Guillermo Izquierdo, Eduardo Aguera [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Retricted access

Research article

First published 2021-3

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate

Viktor von Wyl, Pascal Benkert, André Moser [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2023-4

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine

Sarah Conway, Shrishti Saxena, Clare Baecher-Allan [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Search results